Assessing Recall and Recognition for Important Safety Information in Digital Promotion for Pharmaceutical Products

Abstract

Background:

To date, there has been little research with digital direct-to-consumer (DTC) communication regarding pharmaceutical products (eg, product websites), so this study was designed to measure perception and recall of Important Safety Information (ISI) in websites viewed on desktops and smartphone devices.

Methods:

A quantitative survey was conducted with 1600 self-identified asthma patients. Participants viewed 1 of 4 mocked-up websites for a fictitious asthma product in either a desktop or smartphone format that varied in the way in which risk information was presented and accessed. The “websites” were embedded in survey software that enabled behavior to be tracked and facilitated presentation of questions designed to assess memory and user experience.

Results:

Statistically significant differences in likelihood of interacting with, and memory of, the ISI were observed across the 4 different presentation formats—2 typical of existing website formats and 2 representing alternative formats—for both desktop and smartphone media. The traditional formats consistently outperformed the alternative formats overall, but when analyses are restricted to the subset of participants who view ISI, elements of one of the alternative formats proved to be superior.

Conclusions:

Digital presentation of different formats of risk information has a significant effect on recall and recognition of ISI associated with pharmaceutical products, and the interactive nature of digital material adds a layer of complexity to assessing the performance of the various formats.

Keywords

direct-to-consumer advertising digital media regulatory policy

Get full access to this article

View all access options for this article.

References

Stotka

Rotelli

Dowsett

. A new model for communication risk information in direct to consumer print advertisements. Drug Inform J. 2007;41:111–120.

Aikin

O’Donoghue

Swasy

. Randomized trial of risk information formats in direct-to-consumer prescription drug advertisements. Med Decis Making. 2011;31:E23–E33.

Food and Drug Administration. Brief summary and adequate directions for use: disclosing risk information in consumer-directed print advertisements and promotional labeling for prescription drugs: guidance for industry. Revised Draft Guidance. Fed Regist 2015;80(26):6998–7000.

Hicks

Wogarlter

Vigilante

. Placement of benefits and risks in prescription drug manufacturers’ websites and information source expectations. Drug Inform J. 2005;39:267–278.

Vigilante

Wogalter

. Assessing risk and benefit communication in direct-to-consumer medication website advertising. Drug Inform J. 2005;39:3–12.

Jones

Marsden

Mohd-Nasir

Boone

. Improving web interaction on small displays. Computer Networks. 1999;31:1129–1137.

Baker

. The impact of paging vs. scrolling on reading online text passages. Software Usability Research Laboratory, Wichita State University. http://usabilitynews.org/the-impact-of-paging-vs-scrolling-on-reading-online-text-passages. Published February 11, 2003.

Hoy

Levenshus

. A mixed-methods approach to assessing actual risks readership on branded drug websites [published online ahead of print August 27, 2016]. J Risk Res. http://dx.doi.org/10.1080/13669877.2016.1223160.